So what is a patient to conclude? Doctors are supposed to make recommendations… mine says to install this device to preclude a stroke… so WTF???? I need a definitive answer and all I read is controversy … do it! Don’t do it!! Mother of GoD… I hate the medical community
Finally, some reason! I was one of your CRM reps at Guidant when we met. I was with Guidant then Boston Scientific when Watchman was being developed. I was not impressed. Certainly we could do better. Exchanging one systemic therapy for a focal therapy without clear systemic benefit is immoral. But Watchman will make a lot of money for BSC and has already made some careers.
Finally, some reason! I was one of your CRM reps at Guidant when we met. I was with Guidant then Boston Scientific when Watchman was being developed. I was not impressed. Certainly we could do better. Exchanging one systemic therapy for a focal therapy without clear systemic benefit is immoral. But Watchman will make a lot of money for BSC and has already made some careers.
Have you seen any new studies to change your opinion in this?
What is your position now that we have more data? Watchman vs Xarelto? Periodic bleeding from prostate.
So what is a patient to conclude? Doctors are supposed to make recommendations… mine says to install this device to preclude a stroke… so WTF???? I need a definitive answer and all I read is controversy … do it! Don’t do it!! Mother of GoD… I hate the medical community
what about closing the appendage from the outside? If stroke is a systemic problem, shouldn't the whole population be on blood thinners??
Finally, some reason! I was one of your CRM reps at Guidant when we met. I was with Guidant then Boston Scientific when Watchman was being developed. I was not impressed. Certainly we could do better. Exchanging one systemic therapy for a focal therapy without clear systemic benefit is immoral. But Watchman will make a lot of money for BSC and has already made some careers.
Finally, some reason! I was one of your CRM reps at Guidant when we met. I was with Guidant then Boston Scientific when Watchman was being developed. I was not impressed. Certainly we could do better. Exchanging one systemic therapy for a focal therapy without clear systemic benefit is immoral. But Watchman will make a lot of money for BSC and has already made some careers.